Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

EpiCast Report: Cushings Syndrome - Epidemiology Forecast to 2023

Published: Oct-2014 | Format: PDF | GlobalData | Number of pages: 58 | Code: MRS - 2059

 

Cushing's syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action. CS is associated with increased mortality caused by complications due to excess cortisol.

 

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, with an annual growth rate of 0.59% in the forecast period. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases.

 

For this analysis, GlobalData epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing's disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM. The forecast provides the ageand sex-specific diagnosed prevalent cases of CS subtypes in the six markets, providing a comprehensive view of CS. In addition, this analysis provided detailed, clinically relevant segmentations for Cushing's disease in order to improve the management of the disease.

 

Scope

 

  • The Cushing's syndrome (CS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing's disease, ectopicadrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to =85 years) and sex in these markets.
  • The CS epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

 

Reasons to buy

 

  • Develop business strategies by understanding the trends shaping and driving the global CS market.
  • Quantify patient populations in the global CS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CS therapeutics in each of the markets covered.

Table of Contents

 

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

 

2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Related Reports 8

 

3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 11
3.3.1 US 11
3.3.2 5EU 11
3.4 Forecast Methodology 12
3.4.1 Sources Used 15
3.4.2 Sources Not Used 17
3.4.3 Forecast Assumptions and Methods - Prevalent Cases 18
3.4.4 Forecast Assumptions and Methods - Immediate TSS Outcomes 19
3.5 Epidemiological Forecast of Cushing's Syndrome (2013-2023) 19
3.5.1 Cushing's Syndrome 19
3.5.2 Cushing's Disease 25
3.5.3 Ectopic ACTH CS 31
3.5.4 Adrenal Adenoma CS 36
3.5.5 Adrenal Carcinoma CS 41
3.5.6 Age-Standardized Diagnosed Prevalence Rates 46
3.5.7 Immediate TSS Outcomes 48
3.6 Discussion 49
3.6.1 Epidemiological Forecast Insight 49
3.6.2 Limitations of the Analysis 49
3.6.3 Strengths of the Analysis 50

 

4 Appendix 51
4.1 Bibliography 51
4.2 About the Authors 53
4.2.1 Epidemiologists 53
4.2.2 Reviewers 54
4.2.3 Acting Director of Epidemiology 55
4.2.4 Global Head of Healthcare 55
4.3 About GlobalData 56
4.4 About EpiCast 56
4.5 Disclaimer 57

 

List of Tables

 

Table 1: Risk Factors for Cushing's Syndrome 11
Table 2: 6MM, Sources of CS Prevalence Data 13
Table 3: 6MM, Diagnosed Prevalent Cases of CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 20
Table 4: 6MM, Age-Specific Diagnosed Prevalent Cases of CS, Both Sexes, N (Row %), 2013 22
Table 5: 6MM, Sex-Specific Diagnosed Prevalent Cases of CS, Ages ?18 Years, N (Row %), 2013 24
Table 6: 6MM, Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 26
Table 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Cushing's Disease, Both Sexes, N (Row %), 2013 28
Table 8: 6MM, Sex-Specific Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, N (Row %), 2013 30
Table 9: 6MM, Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 32
Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Both Sexes, N (Row %), 2013 33
Table 11: 6MM, Sex-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, N (Row %), 2013 35
Table 12: 6MM, Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 37
Table 13: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Both Sexes, N (Row %), 2013 38
Table 14: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, N (Row %), 2013 40
Table 15: 6MM, Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 42
Table 16: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Both Sexes, N (Row %), 2013 43
Table 17: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, N (Row %), 2013 45
Table 18: 6MM, Immediate TSS Outcomes, Both Sexes, N, 2013 49

 

List of Figures

 

Figure 1: 6MM, Diagnosed Prevalent Cases of CS, Ages ?18 Years, Both Sexes, N, 2013-2023 21
Figure 2: 6MM, Age-Specific Diagnosed Prevalent Cases of CS, Both Sexes, N, 2013 23
Figure 3: 6MM, Sex-Specific Diagnosed Prevalent Cases of CS, Ages ?18 Years, N, 2013 25
Figure 4: 6MM, Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, Both Sexes, N, 2013-2023 26
Figure 5: 6MM, Age-Specific Diagnosed Prevalent Cases of Cushing's Disease, Both Sexes, N, 2013 29
Figure 6: 6MM, Sex-Specific Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, N, 2013 31
Figure 7: 6MM, Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, Both Sexes, N, 2013-2023 32
Figure 8: 6MM, Age-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Both Sexes, N, 2013 34
Figure 9: 6MM, Sex-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, N, 2013 36
Figure 10: 6MM, Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, Both Sexes, N, 2013-2023 37
Figure 11: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Both Sexes, N, 2013 39
Figure 12: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, N, 2013 41
Figure 13: 6MM, Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, Both Sexes, N, 2013-2023 42
Figure 14: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Both Sexes, N, 2013 44
Figure 15: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, N, 2013 46
Figure 16: 6MM, Age-Standardized Diagnosed Prevalence of CS (%), Ages ?18 Years, 2013 47
Figure 17: 6MM, Age-Standardized Diagnosed Prevalence of Cushing's Disease (%), Ages ?18 Years, 2013 48

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3995 View Pricing